Response to: 'Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease' by Orlandoet al.
Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.|VIB Inflammation Research Centre, Ghent University, Ghent, Belgium.
G
G
Varkas
Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.|VIB Inflammation Research Centre, Ghent University, Ghent, Belgium.
F
F
Van den Bosch
Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.|VIB Inflammation Research Centre, Ghent University, Ghent, Belgium.
D
D
Elewaut
D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D015212:Inflammatory Bowel Diseases; D058566:Sacroiliitis; D025241:Spondylarthritis
D061067:Antibodies, Monoclonal, Humanized; C543529:vedolizumab
Arthritis; Inflammation; Spondyloarthritis; Treatment